KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Cash from Investing Activities (2016 - 2025)

Amgen has reported Cash from Investing Activities over the past 17 years, most recently at -$693.0 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$693.0 million for Q4 2025, down 72.39% from a year ago — trailing twelve months through Dec 2025 was -$1.9 billion (down 85.76% YoY), and the annual figure for FY2025 was -$1.9 billion, down 85.76%.
  • Cash from Investing Activities for Q4 2025 was -$693.0 million at Amgen, down from -$414.0 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for AMGN hit a ceiling of $1.4 billion in Q1 2023 and a floor of -$27.1 billion in Q4 2023.
  • Median Cash from Investing Activities over the past 5 years was -$264.5 million (2022), compared with a mean of -$1.7 billion.
  • Biggest five-year swings in Cash from Investing Activities: crashed 1410.0% in 2022 and later surged 1323.42% in 2023.
  • Amgen's Cash from Investing Activities stood at -$230.0 million in 2021, then crashed by 1410.0% to -$3.5 billion in 2022, then tumbled by 679.99% to -$27.1 billion in 2023, then surged by 98.52% to -$402.0 million in 2024, then crashed by 72.39% to -$693.0 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$693.0 million (Q4 2025), -$414.0 million (Q3 2025), and -$389.0 million (Q2 2025) per Business Quant data.